News

Funds for MDx manufacture
Enlarge image

FinancingBelgium

Funds for MDx manufacture

20.07.2016 - Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Biocartis managed to secure a €40m bank and lease financing facility as well as a €15m subordinated loan. The Mechelen-based company will use the funds to finance the expansion of Biocartis’ manufacturing capacity for its Idylla diagnostics tests with a second Idylla cartridge manufacturing line that Biocartis ordered at the end of 2015. In addition, the money will refinance an existing loan of €5m and strengthen the company’s financial position to continue to execute its strategic plan.

The bank and lease financing facility was provided by KBC Bank and KBC Lease. It includes a partial guarantee by the Flemish Government through Gigarant. The new subordinated loan is provided by a consortium of Flemish investment company PMV and the Belgian Federal Holding and Investment Company (FPIM). It has a duration of five years. 

“The new bank facility and subordinated loan strengthen our capitalisation and will further support us in realising our ambitious growth trajectory,” commented Ewoud Welten, Chief Financial Officer of Biocartis. “It also underlines Biocartis’ ability to attract funding beyond equity capital markets from reputable debt financing partners that acknowledge our potential within the molecular diagnostics market.”

Roald Borré, Head of Equity Investments of PMV, added: “Enabling companies like Biocartis to be successful positively impacts the Belgian economy in terms of employment and growth of local knowledge. Both being elements that FPIM and PMV actively want to support.”

© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2016-03/funds-for-mdx-manufacture.html

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/5.html

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • PROTHENA PLC (IE)52.22 USD47.2%
  • FLAMEL TECHNOLOGIES (F)12.58 USD33.1%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%

FLOP

  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%

TOP

  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%

FLOP

  • BB BIOTECH (D)45.00 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016